They set an "outperform" rating and a $58.00 price target on the stock. Janus Henderson Group PLC now owns 704,673 shares of the biotechnology company's stock valued at $36,460,000 after acquiring an additional 696,640 shares during the last quarter. (NASDAQ:SGEN). 426,129 were reported by Savings Bank Of New York Mellon Corporation. ValuEngine cut shares of Seattle Genetics from a hold rating to a sell rating in a research note on Friday, July 28th. BidaskClub lowered shares of Seattle Genetics from a hold rating to a sell rating in a research note on Wednesday, June 28th. It dived, as 30 investors sold Seattle Genetics, Inc. shares while 75 reduced holdings. Cantor Fitzgerald reissued a hold rating and set a $43.00 price target on shares of Seattle Genetics in a report on Monday, June 26th. Royal Bank Of Canada began coverage on Seattle Genetics in a research note on Thursday, September 14th. Three research analysts have rated the stock with a sell rating, twelve have issued a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of Hold and a consensus price target of $61.65.
Seattle Genetics (SGEN) traded up 1.21% during trading on Friday, hitting $61.93. Blackrock accumulated 565,487 shares or 0% of the stock. The company's 50-day moving average is $57.04 and its 200 day moving average is $57.64. The company's market capitalization is $7.08 billion.
With a total market value of $0, Seattle Genetics has with a one year low of $45.31 and a one year high of $75.36.
Seattle Genetics (NASDAQ:SGEN) last announced its quarterly earnings data on Thursday, July 27th.
Marcell Dareus Traded to Jaguars for 6th-Round Draft Pick
The Buffalo Bills have been trying to move the contract of defensive tackle Marcell Dareus for quite some time now. The Jaguars might not be pretty on offense, but their defense is good enough to get them to the playoffs.
In terms of earnings per share, 15 analysts have a -0.44 EPS mean target for the quarter ending Dec-17, for the quarter ending Mar-18, 4 analysts have a -0.41 EPS mean target and for the quarter ending Mar-18 there are 16 estimates of -1.68 EPS. Seattle Genetics had a negative return on equity of 32.87% and a negative net margin of 47.38%. The firm earned $95.40 million during the quarter, compared to analysts' expectations of $94.56 million. With the last close up 8.19% from the two hundred day average, compared with the S&P 500 Index which has increased 0.03% over the same period. The firm's revenue for the quarter was up 27.3% on a year-over-year basis. On average, equities analysts forecast that Seattle Genetics will post ($1.00) earnings per share for the current year.
TRADEMARK VIOLATION WARNING: This news story was reported by Week Herald and is the sole property of of Week Herald. If you are reading this story on another domain, it was illegally copied and republished in violation of global copyright and trademark laws. (NASDAQ:SGEN). Vanguard Grp invested 0.02% in Seattle Genetics, Inc.
In related news, EVP Darren S. Cline sold 6,000 shares of the firm's stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $47.89, for a total transaction of $1,221,482.34. The sale was disclosed in a filing with the SEC, which is available at this link. The disclosure for this sale can be found here. Over the last three months, insiders have sold 173,761 shares of company stock worth $8,949,050. BlackRock Inc. now owns 7,267,660 shares of the biotechnology company's stock valued at $456,845,000 after acquiring an additional 7,154,776 shares during the last quarter. The firm earned "Buy" rating on Monday, February 27 by Argus Research.
Seattle Genetics, Inc.is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. Crossmark Global Holdings Inc. bought a new stake in Seattle Genetics in the third quarter worth about $274,000. Janus Henderson Group PLC raised its holdings in Seattle Genetics by 8,672.2% in the 2nd quarter. Janus Capital Management LLC now owns 527,400 shares of the biotechnology company's stock valued at $33,153,000 after acquiring an additional 402,200 shares during the last quarter. Capital International Investors now owns 2,724,589 shares of the biotechnology company's stock valued at $140,970,000 after acquiring an additional 695,986 shares during the last quarter. Pictet Asset Management Ltd. raised its position in Seattle Genetics by 79.3% in the third quarter. Finally, Marshall Wace North America L.P. boosted its holdings in shares of Seattle Genetics by 1,605.7% during the 2nd quarter. Baillie Gifford And holds 1.1% in Seattle Genetics, Inc. Eventide Asset Management Llc, a Massachusetts-based fund reported 525,000 shares. Hedge funds and other institutional investors own 97.64% of the company's stock. The Firm is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others.
- Luke Kuechly, Kurt Coleman heading in right direction
- F5 Networks, Inc. (FFIV) Earns "Buy" Rating from Drexel Hamilton
- WVU's Mountaineer mascot arrested for DUI
- Kathy Griffin, Done Apologizing, Is Ready for Her Comeback
- The Netflix (NFLX) - Investment Analysts' Recent Ratings Updates
- Astronomers discover blistering planet where sunscreen falls from the sky like snow
- Russian Election Interference? RT Publishes Twitter Ad Campaign Proposal After Advertisements Banned
- Another 'Ace Ventura' Movie Might Happen, If Jim Carrey Is Interested
- Trump orders acceleration of repairs to Florida's Herbert Hoover Dike
- UBS Group Q3 Profit Climbs, Net Interest Income Down